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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, 
mortality, disability, and cost globally and in the United States. Various sources point to 
women experiencing greater morbidity, increased health care resource use and higher 
incidence of mortality resultant from COPD. While exact causality is not fully 
understood, it is possible that social bias towards COPD in women impacting screening 
and timely diagnosis may be a contributing factor. This current investigation involved the 
social ecological model. In this cross-sectional secondary analysis of Behavioral Risk 
Factor Surveillance System, 2017 data, differences in screening through use of breathing 
testing among 6334 males and females who have knowledge of COPD were assessed 
through descriptive statistics, Pearson’s chi-squared test, and binomial logistic regression 
(BLR). Bivariate analysis indicated a marginally significant association between sex and 
participation in breathing tests (χ
2 
= 3.44, p = 0.063), disproportionately impacting 
women who used tests less. According to BLR models, females were 15.9% more likely 
not to take the breathing tests compared to males (OR = .841, CI 95%: 0.739-0.961) 
adjusted for COPD symptoms, and females were 11.7% more likely not to take the 
breathing test when controlling for healthcare coverage, but this result was marginally 
significant (OR=.883 CI 95%: .775-1.007). This study can offer insight into the use and 
patterns of breathing testing among the US population while further describing potential 
gaps in care, serving as catalyst towards driving necessary education, policy development 
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Section 1: Foundation of the Study and Literature Review 
 World Health Organization, global authority in public health, has described 
chronic obstructive pulmonary disease (COPD) as one of the leading causes of morbidity, 
mortality, and cost globally and the United States (World Health Organization [WHO], 
2017). In 2016, the global burden was estimated at 251 million cases, with a US footprint 
of roughly 27 million as described by the Centers for Disease Control and Prevention 
(CDC), US authority in public health (Centers for Disease Control [CDC], 2016). Little is 
understood about specific variances within the general population; however, mortality 
due to disease is dense in low-middle income countries, which is hypothesized to be 
somewhat related to environmental high levels of indoor and outdoor air pollution as well 
as exposure to tobacco (Quaderi, 2018). The American Thoracic Society suggests the 
next 15 years will elevate COPD as the primary killer globally when considering current 
societal exposure to tobacco and indoor air pollution while superimposing an aging 
population (ATS, 2018). 
COPD is known to follow prolonged exposure to noxious particles, complicated 
by the slow onset of symptoms which progress in severity and persistency over time. For 
patients, symptoms of shortness of breath and cough take time to be recognized; 
typically, activity modification is implemented prior to seeking medical attention.  These 
complexities contribute to patients’ limited understanding of prevalence and diagnostic 
patterns; therefore, clinical interaction is necessary for testing and formal assessment.  
Moreover, COPD was perceived to be an illness mainly observed in men; therefore, 
inherent biases continue to burden attitudes towards women (WHO, 2019).   
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This study explored relationship between sex and subsequent diagnostic patterns 
in COPD to ascertain whether a sex bias, specifically regarding women, towards 
breathing testing exists. CDC’s Behavioral Risk Factor Surveillance System (BRFSS) 
2017 dataset was utilized for this secondary analysis to assess occurrence of diagnostic 
testing between males and females who were told by healthcare providers that they have 
COPD.  This study should guide policymakers, clinicians, researchers, advocacy groups, 
and patient educators towards recognizing these intrinsic biases, their implication for 
patients’ disease management, and quality of life.  Moreover, necessary actions should be 
taken to reduce time to diagnosis and improvement in outcomes for all patients with 
COPD.  
Section 1 explores rationale for investigation supported by an extensive literature 
review.  Moreover, methodology and application to theory and practice are introduced. 
The following sections include the problem statement, purpose of the study, research 
questions and hypotheses, theoretical foundation for the study, nature of the study, 
literature search strategy, literature review & variables, definitions, assumptions, scope 
and delimitations, significance, summary, and conclusions.  
Problem Statement 
COPD has recently demanded attention from a multitude of stakeholders on a 
global and local scale, as burden of illness is alarming. Complicating the issue is the lack 
of consensus regarding capturing accurate prevalence of COPD prevalence (Diaz-
Guzman, 2014).  Because the illness is progressive, while symptoms of shortness of 
breath may have alternate causality, diagnostic testing through the use of pulmonary 
3 
 
function testing is recommended by governing expert panels (GOLD, 2020). Spirometry 
is a functional breathing assessment with minimal invasiveness; therefore, it is unlikely 
that early detection initiatives would cause harm.  United States Preventative Task Force 
[USPTF] (2016) suggests that asymptomatic adults should not undergo screening even if 
at risk; instead, active “case finding” should be practiced by clinicians.  Active case 
finding would prompt a clinician to recommend breathing tests if a patient has active and 
burdensome symptoms with a known risk factor. Out of the estimated 24 million 
individuals in the US with signs and symptoms of COPD, only 15.7 million actually have 
an accurate diagnosis (NIH, 2018).  Underdiagnoses is problematic, as patients may be 
likely to delay treatment, suffering potentially negative outcomes.  Chronic Respiratory 
Disease Collaborators (GBD) (2017) found an increase of over 11% in death causalities 
due to COPD since 1990, while overall age-related deaths have steadily declined.   
American population does not experience COPD homogeneously; in fact, several 
societal trends are observed.  Centers for Disease Control and Prevention (2012) suggests 
that Hispanics are less likely to report COPD in comparison to non-Hispanic whites and 
African Americans at 4% vs. 6.3% and 6.1%, respectively.  Education level and 
employment status serve as protective; those with greater degrees of academic 
achievement and employment experience less disease burden. Disease patterns parallel 
those of population segments with higher observed incidents of smoking (CDC, 2012).  
Sex alone is a significant risk factor for both morbidity and mortality in COPD, as 
women are more likely to die as a result of the illness (Mannino, 2013).    
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Within the medical community, COPD was historically viewed as a disease 
predominately affecting Caucasian males (Dransfield, 2006).  Within the century, 
cigarette consumption in the United States experienced rapid uptake by predominately 
Caucasian males during both world wars and the Great Depression.  Following 1964 
Surgeon General Report, steady declines in men were observed (U.S. Department of 
Health and Human Services [DHHS], 2014).  In women, prevalence of smoking varied 
over the same time frame from 5-40%.  Use of cigarettes by women, according to 
multiple surveys, consistently demonstrated a lower consumption rate (Office on 
Smoking and Health (US, 2001).  Aside from social biases and behavioral trends, women 
are more likely to report symptoms and die as a result of COPD (NIH, 2018).  COPD-
related mortality decreased in men by 22 % between 2000 and 2014; progress in women 
decreased by 3.8% over the same period (CDC, 2018). Little evidence is available to 
describe illnesses specifically experienced by women and access to accurate diagnosis.  
This gap in understanding of social stigmatization of disease in women warrants further 
investigation to fully describe societal patterns and ramifications. The intent of this study 
was to evaluate differences in terms frequency of occurrences of diagnostic testing via 
breathing tests between men and women.   
Purpose of the Study 
Considering the immense variabilities in diagnostic patterns of COPD as well as 
potential impacts of sex bias, the objective of this investigation was to describe these 
patterns particularly as they relate to women at risk. This quantitative, cross-sectional 
analysis interrogated the BRFSS 2017 database to describe diagnostic patterns among 
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men and women; specifically, subjects who have been told by healthcare providers that 
they have COPD and response to breathing tests construct.  Examination of these findings 
should inform researchers, clinicians, public health practitioners, and policy makers in 
driving social change.  This may include education across societal sectors, working 
towards   population screening, timely diagnosis and intervention for all patients at risk.  
Research Questions and Hypothesis  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) promotes 
spirometry as a necessary diagnostic assessment contributing to the verification of COPD 
diagnosis. However, societal and organizational dynamics present potential barriers 
which disproportionally affect women.  This study was intended to examine the 
prevalence of breathing tests among men and women who have been told by healthcare 
providers that they have COPD.  It is hypothesized that less diagnostic testing will be 
observed in women, with potential greater presence of symptoms and activity limitations.  
This study interrogated the 2017 BRFSS cohort, a national database surveying 
over 500,000 US adults across 50 states, thereby supporting generalizability of the study. 
RQ1: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD?  
Ho1: There are no differences in terms of use of breathing tests between males and 
females who have been by clinicians told they have COPD. 
Ha1: There are difference in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD. 
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RQ2: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD and experience cough, phlem, 
and shortness of breath?  
Ho2: There are no differences in terms of use of breathing tests between males and 
females who have been told they have COPD and experience cough, phlem, and 
shortness of breath. 
Ha2: There are difference in terms of use of breathing tests between males and 
females who have been told they have COPD and experience cough, phlem, and 
shortness of breath. 
RQ3: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD and access to healthcare?  
Ho3: There are differences in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD and access to healthcare. 
Ha3: There are differences in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD and access to healthcare. 
Theoretical Foundation for the Study 
Screening behaviors of clinicians and patients are driven by beliefs and attitudes, 
further reinforced by social and policy constructs.  A model for this work must 
adequately represent the complexity of COPD diagnostic patterns and societal influences.   
Social Ecological Model (SEM) was applied to the study.  Urie Bronfenbrenner in the 
1970s developed the SEM to describe drivers of human development.  Later, model 
further evolved into a theoretical framework delineating external influences on human 
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beliefs and actions (Kilanowski, 2017).  This theoretical framework is grounded on 
individual attitudes and beliefs towards an idea; recognizing influence of interpersonal, 
organizational, community, and policy dynamics surrounding phenomena. SEM 
framework has been applied in many public health research and intervention initiatives to 
describe various phenomena while stimulating process improvement. The CDC has 
applied this model towards stimulating and driving participation in the National Breast 
and Cervical Cancer Early Detection Program (NBCCEDP) for greater participation in 
screening.   
The SEM can be implemented to describe flow of perception within the system 
involving sex-based trends in COPD screening. Recognizing systemic societal concerns 
involving COPD as they relate to women is essential. 
 
Figure 1.  Social Ecological Model applied to societal biases in COPD 
Nature of the Study 
For this investigation, a cross-sectional, secondary, quantitative methodology was 
applied. CDC’s BRFSS was established in the 1980s with the intent of collecting self-
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reported behaviors and risks across the US populace; since its initiation with 15 
participating states, data is collected via monthly telephone surveys across 50 states as 
well as the District of Columbia, American Samoa, Palau, Puerto Rico, US Virgin 
Islands, and Guam.  With more than 500,000 case interviews for this broad population, , 
this data set is ideal for investigation and observation of potential trends.  Participants in 
the survey were randomly selected adults who were 18 and older.  A cross-sectional 
analysis was selected for this investigation due to the observational nature of the study.  
A descriptive analysis of the population was completed.   
Literature Search Strategy 
For this investigation, three primary databases, PubMed, Medline and ProQuest, 
were used with the assistance of two libraries (AstraZeneca Library Portal and Walden 
University).  Key words used for the literature review were chronic obstructive 
pulmonary disease, COPD, epidemiology, morbidity, mortality, healthcare cost, smoking, 
tobacco related illness, diagnosis, pulmonary function testing, sex, gender, social 
ecological model, and public policy.  I concentrated on recent literature published 
between 2013 and 2019.  Studies describing COPD and diagnostic journeys experienced 
by women are significantly lacking, as is information about sex-related bias is limited.   
Literature Review  
Background  
COPD is characterized by persistent airflow limitation which predominately 
results from biological processes subsequent to exposure of the lung to environmental 
risks, specifically prolonged tobacco smoking and household air pollution (ATS, 2018).  
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Obstruction of the airway is a product of tissue destruction, inflammation, and bronchial 
narrowing, all leading to the compromised ability of air to move in and out of the lung. 
Disease frequently presents as burdensome respiratory symptoms such as shortness of 
breath, coughing, and production of mucous leading to significant limitation of activity.  
Moreover, faster decline in lung function in these patients is observed. Exacerbations, 
periods of disease worsening, are frequent as the airway pathology is altered and can be 
easily triggered by common viruses and environmental pollutants.   
Prevalence  
Global burden of obstructive lung disease is estimated at 251 million cases, of 
which, roughly 27 million are in the United States (WHO, 2017). Generally, those of 
lower socioeconomic status are more likely to experience disease.  Because illness 
progresses with symptoms developing over time, without advocacy for population wide 
screening, it is difficult to identify cases early. 
 The effect of COPD expenditures on US healthcare budget is exorbitant.  In the 
year 2000, there were over 8 million outpatient visits, 1.5 million emergency visits, and 
726,000 hospitalizations resulting from COPD (Mannino, 2017).  Patients with COPD are 
also more likely to be re-hospitalized.  Because patients with COPD have multiple 
comorbidities, direct and indirect costs are underestimated; patients may be hospitalized 
for other reasons which are further complicated by COPD.  Patients with COPD have 
been reported to have a 22.8% burden of disability than those without, 7.3% (Mannino, 
2017); as such, total medical expenditure is higher.  End of life care for patients with 
COPD frequently requires intensive care, thereby leading to additional assumed costs. 
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Small-scale screening interventions have been successful in identifying patients earlier in 
the disease process.  Broad scale screening programs for patients at risk for COPD may 
incrementally increase costs; however, intervention earlier promises to hinder the already 
burdensome and expensive trajectories.  
Diagnosis and Treatment  
GOLD (2018) suggests that patients with known risk and symptoms should 
undergo lung function testing, confirming diagnosis and establishing degree of airflow 
obstruction.  Because breathing abnormalities can have varied pathologies, pulmonary 
function testing serves as proper confirmatory procedure.  Disease severity is sequentially 
established based on degree of airflow obstruction, presence and burden of symptoms and 
risk for exacerbations.  
Treatment of illness involves two main goals: reducing symptoms and limiting 
risks (GOLD, 2018).  Nonpharmacologic treatment includes pulmonary rehabilitation as 
continuance of physical activity has exhibited positive outcomes in patients (McCarthy, 
2015).  Pharmacologically, vaccines and inhalations therapies for patients have shown 
both an improvement in lung function, reductions of exacerbations, and slowing of lung 
function decline (Celli, 2014).  Reflecting on pharmacologic treatment patterns in the US, 
a tremendous opportunity to optimize exists.  Diette and colleagues (2015) observed that 
45% of COPD population was receiving maintenance therapy while 69% was on rescue 
treatment.  It is possible that underdiagnosis and undertreatment are related as one may 
lead to the other; however, this is beyond the scope of this investigation.  Additional 
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research is necessary to understand suboptimal treatment patterns across COPD patients, 
specifically, fragile groups such as women and those of lower socioeconomic status. 
COPD and Trends in Women 
  Reflecting on the experience of women within the healthcare system, 
disproportionality across therapeutic areas is observed; suggesting that certain chronic 
diseases are faced to a greater burden and severity in this patient population (Smith 
2013).   Agency for Healthcare Research and Quality describes disproportionate trends in 
cardiovascular, metabolic, bone, psychiatric and HIV/AIDS in women, emphasizing 
nuances detected within female population are unfavorable while calling for much 
needed awareness, evidence generation and policy change (AHRQ, 2012). Several 
diseases are observed to present differently in women. For example, cardiovascular 
disease is the leading killer of men and women alike; however, 42% of women die within 
the first year following a heart attack in comparison to 24% of men (Agency for 
Healthcare Research and Quality [AHRQ], 2012).  Women are more likely to receive 
delayed diagnosis and aggressive treatment in comparison to men (AHRQ, 2012). 
Observance of these important phenomena, both biologically and socially, have led to 
myriad of questions in multiple therapeutic areas with the intent of understanding 
causalities and possible opportunities.   
 Reflecting on current body of evidence specific to COPD patterns, similar 
distinctions are observed.  While respectable gains through the reduction of COPD 
related mortality have been observed in men, the same target have been stagnant in 
women (Diaz-Guzman, 2014); COPD is the 4th leading cause of death in the United 
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States, however, in women, it’s the 3rd (CDC, 2018). It is also apparent that women, 
commonly, have greater morbidity from the illness, defined through a greater utilization 
of the healthcare system. Mechanistically, some exploration has been done to understand 
the impact of tobacco exposure to the male and female lung.  Certain epigenetic 
causalities are hypothesized, specifically, maternal exposure to fetus and hormones 
(Dransfield, 2006). Causality of maternal tobacco exposure to the fetus increases to the 
risk of offspring developing lung disease, severity is greater in female children. 
Additionally, certain evidence has pointed to tobacco exposure and sequential pathology.  
Interestingly, women cultivate disease with less noxious particle ‘dose’ as compared to 
men.  A study by Nakano et al. utilized computed tomography techniques evaluating lung 
pathology, determining that women had greater pathology compared to men with similar 
and even less smoking exposure (Nakano, 2000). These distinctions are important for 
research as traditionally randomized trials in COPD require subjects 40 years of age and 
greater with 10-year smoking pack smoking history; this evidence suggests that tobacco 
exposure for women is potentially less, therefore, a significant proportion of female 
patients are under-represented in studies.   
Publicly, COPD is accompanied by societal bias.  Because the illness is 
considered a product of a health hazardous behavior, a perception of “fault” is not 
uncommon among society.  This sensitivity is potentially detrimental for patients as they 
are discouraged from and ashamed to seek care and therefore delay interventions.  
Collectively, this is further complicated by an unspoken bias within the healthcare 
community possibly affecting both appropriate diagnosis and treatment (Mamary, 2018). 
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The majority of research continues to regard COPD as a disease primarily observed in 
men.  Chapman and Tashkin (2001) said “only 57% of physicians offered COPD as the 
most likely diagnosis following presentation of the history and physical 
examination…[furthermore] COPD was significantly more likely to be offered as the 
provisional diagnosis for the hypothetical male patient than the hypothetical female 
patient” (p. 1693).  In a recent study by the COPDGene group it was also noted that 
women generally manifest greater burden of symptoms and earlier in age as compared to 
males (DeMeo, 2018). It is unknown however how presence of symptoms and risk 
translate to diagnostic patterns. Aggregating signals point to sex differences in the 
prevalence, susceptibility to, severity of, and response to treatment and management of 
chronic obstructive pulmonary disease. This gap may be specifically problematic for 
women, for example, because they may not be adequately informed of the symptoms of 
COPD, appropriately screened for the disease, or receive appropriate interventions and 
treatment.  
Definitions 
Chronic Obstructive Pulmonary Disease (COPD): A common, preventable, and 
treatable disease of the respiratory system involving persistent symptoms and airflow 
limitations due to airway abnormalities typically caused by prolonged exposure to 
noxious particles and gasses (GOLD, 2018). 
Gender: Socially accepted characteristic of males and females which involve 
physically observable traits, norms, and societal roles (WHO, 2019). 
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Gender Bias: In the context of healthcare, gender bias is prejudice in terms of 
perceptions  
Health Care Resource Use: Consumed services or goods used by patients 
resulting from interactions between patients and the healthcare system (Da Silva, 2011). 
Pulmonary function testing/Spirometry: A group of breathing tests evaluating air 
flow, lung volumes, gas exchange, and inflammatory markers (NIH, 2018).   
Sex: A biological characteristic typically assigned at birth describing natural 
chromosomal, internal, and external reproductive organs (APA, n.d.). 
Smoking Pack History: A calculation of number of packs smoked per day for the 
number of years a subject has smoked (GOLD, 2018). 
Assumptions 
Reflecting on observed prevalence, mortality trends in women, as well as known 
generalized perceptions about COPD, subjects’ sex may have an influence on diagnostic 
patterns.  BRFSS 2017 patient population were queried regarding symptoms of 
obstructive lung disease and knowledge regarding COPD according to healthcare 
providers.  Additionally, subjects reported undergoing breathing testing suggested use of 
a screening tool to support the diagnosis as per GOLD recommendations. No known 
recall bias was described between males and females pertaining to disease and diagnosis 
history; therefore, it was assumed that trend comparison is acceptable.     
Scope and Delimitations 
Considering the design of the study and nature of the dataset, this examination 
was cross-sectional design and descriptive, aiming to determine COPD- related 
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diagnostic patterns, specifically as they are observed between males and females. The 
study population included male and female participants who were able to read and write 
and therefore could self-report their medical history. The BRFSS 2017 queried 
participants in 50 states across the US, the District of Columbia, American Samoa, Palau, 
Puerto Rico, US Virgin Islands, and Guam; therefore, the breadth of the patient 
population allowed deductions to be generalizable at the national level.  The original 
dataset enrolled subjects engaging with the survey team, and therefore no selection bias 
was observed, and the sample was representative of the general population. For this 
analysis, participants were male and female respondents who have been told that they 
have COPD and have responded to breathing tests query.  Understanding of illness is 
complex and can be dependent on perceptions towards disease, access to healthcare, and 
biases within the healthcare system, and as such, signals within this investigation were 
intended to be descriptive, rather than point to causality.  Further exploration of causality 
may be warranted, driving potential opportunities for intervention and social change.    
Study Boundaries  
Selection bias is a significant limitation of this study.  As with most secondary 
analyses, there is little influence on the study population, constructs collected, and 
methodology utilized for collection and data entry; therefore, variable analysis relies on 
participant reported history rather than authentic medical record.  Original data surveyed 
subjects across general health, risks and utilization of resources; COPD being a module 
within the general survey, data is not specific towards a targeted COPD population.  It is 
described that patients may understand, and experience disease differently, therefore may 
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not be generalizable to the broader population who is symptomatic, yet not engaging 
within the healthcare system for care.  Additionally, because BRFSS 2017 is a US 
specific dataset, description may only allude to patterns in the US.  Utilizing caution 
when interpreting these is warranted as subject numbers within the specific nations are 
not balanced.   
Generalizability and Scope  
BRFSS captured survey responses from the broader population of US and its 
territories, as such, generalizability of results may be imposed on the general population 
within surveyed geography. Because this population is gathered in a non-clinical setting, 
trends may be generalizable to mainstream population, as opposed to limiting to only 
those seeking care for their illness.  Scope of investigation was to subjects who have been 
told by healthcare provider that they may have COPD, with rest of the cases excluded to 
focus on relevance to research question.  Confounders of study include geographical 
influences, race-ethnicity, cultural beliefs around COPD, socioeconomic factors, 
education, and marital status.  With the utilization of the 2017 dataset, previous trends 
were not investigated. 
Significance of the Study 
Significance to Theory  
SEM allows for a deconstruction of an observed phenomena across layers of 
society.  On a macro level, recognizing overall under-diagnosis patterns, particularly as 
experienced by women, can guide a shift in public policy towards population screening 
and overall stigmatization of this disease.  At the core are individual beliefs by both 
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clinicians and patients alike. Similarly replacing views of sex bias in prevalence driving 
towards timely diagnosis stands the capability to impact interpersonal, organizational and 
community norms.  The intent is to drive public acceptance and policy around COPD as 
it relates to women while synergizing with grass roots efforts on an individual level.    
Significance to Practice  
Recognizing sheer burden of COPD in the United States, alarming indicator of 
staggering under-diagnosis, complicated by societal biases towards disease in women 
warrants further investigations in terms of understanding diagnostic patterns and possible 
ramifications.  Examining time to diagnosis, disease severity upon diagnosis as 
experienced by male and female patients can offer necessary evidence to guide further 
research and potential intervention across societal sectors with the intent of changing 
attitudes and beliefs towards COPD with the anticipated behavior change of timely 
diagnosis and population wide screening policy.  
Significance to Social Change  
The USPSTF has been a loud opposing body to COPD screening programs.  
Following their systematic review, the group recommended against screening 
asymptomatic patients for COPD, suggesting that benefits do not outweigh risks 
(USPSTF, 2016).  Their work in evaluating currently available data is respectable yet 
fails to consider success and long-term impact of previously executed programs. The 
USPSTF, fails to consider the magnitude of undiagnosed COPD patients.  An 
investigation by Martinez and colleagues discovered that patients who don’t have a 
diagnosis have a greater risk of mortality resulting from COPD (Martinez, 2015).  
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Reflecting on general epidemiologic trends, impact of delays to diagnosis has also been 
correlated to greater morbidity and lower quality of life (Diaz-Guzman, 2014). It must 
also be noted that previously executed screening programs in different therapeutic areas 
have shown capability to halt these trajectories.  
Clearly, this particular issue bears a significant magnitude of scientific merit and 
advocacy, yet, has been less than successful in becoming a political priority.  Much of 
this, possibly, is the discouragement by the USPSTF.  Moreover, because screening 
programs are expensive, political support and therefore fund allocation is necessary. An 
upstream approach to burdens observed resulting from COPD could provide a long term, 
sustainable solutions.  As such, a consideration and politicization of COPD screening 
programs is essential. 
Borrowing a page from the history of breast cancer, a leading cause of cancer in 
women, much is to be celebrated in the proposal and adoption of Breast Cancer 
Screening Programs.  Through the work of cross collaborative stakeholders, including the 
ACS, guideline agencies, and US DHHS, breast cancer screening policies and sequential 
interventions have been successful in identifying early disease in women. Through the 
identification of early cases, more women have survived the diagnosis.  Similarly, 
upstream policies encouraging broad screening for COPD, translated in practice by the 
medical and research communities stand the capability of making an impact on the 
current trajectories.  As is recommended by the GOLD, American Thoracic Society and 
European Respiratory Society, pulmonary function testing must be offered to patients 
with a risk factor for COPD.  Evidence from this investigation can further elevate the 
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hypothesized delay to diagnosis as experienced by women, leading awareness, 
intervention, policy and social change.  
Summary 
COPD represents a significant problem to society as the prevalence is high, 
heterogeneously impacting the population. Women have been observed to have greater 
morbidity and mortality resultant from the illness. Understanding nuances in terms of 
confirmatory breathing testing between males and females can offer important insights 
regarding practice patterns and potential biases towards illness.  Additionally, the impact 
of symptoms and healthcare coverage further provides information regarding these 
important tests. With prevalence and morbidity trends projected to continue increasing, 
while significantly contributing to the already stretched healthcare expenditure budget, 
recognizing nuances within the population may serve as a relevant springboard to myriad 
of stakeholders.  Recognizing sex differences and experience with COPD may further 
guide education and advocacy initiatives, perhaps mitigating or preventing previously 




Section 2: Research Design and Data Collection 
Introduction 
COPD prevalence in the United States is underreported, largely due to 
underdiagnoses and barriers toward screening. While some heterogeneity is apparent 
within the general population, women continue to experience greater morbidity and 
mortality. In the United States, more women die as a result of COPD, a trajectory that has 
increased steadily over the last decade (CDC, 2018). The current study intended to 
describe use of breathing tests among women who have been told by healthcare providers 
they had potential COPD.  Acknowledging patterns towards lung function testing can 
describe whether a latent sex bias towards this diagnostic and treatment tool exists, 
possibly leading towards future exploration and intervention.   Section 2 includes; 
Research Design and Rationale, Methodology, Population, Sampling and Data 
Collection Procedures, Instrument and Operationalization of Constructs, Threats to 
Validity, Ethical Procedures, and a Summary.  
Research Design and Rationale 
This study aimed to describe patterns involving breathing testing between males 
and females who have knowledge of COPD. Because spirometry is a key diagnostic tool 
and drives treatment decisions, variances based on sex can be instrumental in partially 
describing disease outcomes. The independent variable in this study was sex as both men 
and women can develop COPD.  The dependent variable was use of breathing tests 
among the population of subjects who have been told that they may have COPD, 
emphysema, or chronic bronchitis. Moderating variables were symptoms such as 
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shortness of breath, cough and production of phlegm. Additionally, sociodemographic 
factors such as socioeconomic level, education, and presence or absence of healthcare 
coverage were considered moderating variables as these can impact access to pulmonary 
function testing.  
Methodology 
Population  
BRFSS 2017, collected by the CDC, was the data source utilized for this 
secondary analysis. Subjects who had been told they had COPD served as the primary 
analysis population. Furthermore, responses to breathing tests module and age parameter 
were imposed.  Based on the codebook provided by the CDC, final sample size for this 
investigation was 6,334 cases.    
Sampling and Data Collection Procedures  
In order to prevent selection bias, a broad selection strategy was employed by the 
CDC for outbound calling to subjects targeted by the BRFSS sampling strategy. The 
entire 2017 data set included 450, 016 cases; of these, 37, 577 were told they had COPD. 
To further aid in appropriate cohort selection, participants were all older than 35 and had 
received breathing tests.  Subjects within BRFSS- targeted areas had an equal chance of 
being invited to participate in the survey and give consent for participation. The initial 
dataset was entered and maintained by the CDC. 
Sampling frame.  Sampling frame included (a) adults surveyed by BRFSS in 
2017, (b) ages 18 years and older, (c) all reported races and ethnicities, and (d)  those 
responding “yes” to “(Ever told) you have chronic obstructive pulmonary disease, 
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C.O.P.D., emphysema, or chronic bronchitis?” (CDC, 2018).  The COPD cohort was 
extracted from the total population in the database, who have a myriad of non-respiratory 
diseases and should not undergo spirometric testing.  Sample also excluded younger 
cohort (35 years and less) as COPD is unlikely below this age lacking further pathology 
(CDC, 2018).  Selecting the study population was based on a broad and generic question 
such as “having been told of COPD”, provided the best strategy to eliminate bias 
introduced by covariates such as severity of disease, incidence of tobacco use, access to 
care, environmental exposures and behavioral perceptions as the latter should all be 
equally represented within the chosen analysis set.  This specific cohort of subjects 
underwent described sensitivity testing.  
Data accessibility and permission. The BRFSS is an open source dataset and 
can be accessed through the CDC website (BRFSS, 2018).  Data use agreement described 
by the CDC for research purposes and coordinated by the Institutional Review Board 
(IRB) at Walden University, described in the ethics section. Primary dataset collected for 
the purposes of public health surveillance, so, informed consent was exempt. 
Power analysis. Since this was a descriptive cross-sectional analysis, all subjects 
meeting the proposed criteria were analyzed and post hoc power analysis was conducted 
to confirm that the achieved statistical power was adequate (>80%).   
Research Questions and Hypotheses 
RQ1: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD?  
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Ho1: There are no differences in terms of use of breathing tests between males and 
females who have been by clinicians told they have COPD. 
Ha1: There are difference in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD. 
RQ2: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD and experience cough, phlem, 
and shortness of breath?  
Ho2: There are no differences in terms of use of breathing tests between males and 
females who have been told they have COPD and experience cough, phlem, and 
shortness of breath. 
Ha2: There are difference in terms of use of breathing tests between males and 
females who have been told they have COPD and experience cough, phlem, and 
shortness of breath. 
RQ3: Are there differences in terms of use of breathing tests between men and 
women who have been told by clinicians they have COPD and access to healthcare?  
Ho3: There are differences in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD and access to healthcare. 
Ha3: There are differences in terms of use of breathing tests between males and 
females who have been told by clinicians they have COPD and access to healthcare. 
Instrumentation  
BRFSS is a publicly funded open source database operationalized by the CDC; 
this study used the 2017 survey.  BRFSS is populated by random digital dialing across all 
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the states and US territories, collecting health related risk behaviors, chronic health 
conditions and use of preventive services.  The BRFSS completed more than 400,000 
interviews per year making it the largest continuously conducted health survey.  Such a 
database was the optimal tool to answer the research question within this study, due to its 
broad US representation, the breadth of captured data and continuous data acquisition, 
thus making this generalizable across the US. The BRFSS is used by various stakeholders 
and researchers to evaluate behavioral population trends as well as chronic disease 
patterns on both state and federal levels.  
Operationalization of Variables  
Table 1 describes relevant demographic variables explored in this investigation. 
Account of age, race/ethnicity, marital status, income and education level will offer 
description of patient population of interest. 
Table 1 
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Table 2 describes variables necessary to operationalize research questions. 
Variables include sex, receipt of breathing tests to diagnose breathing problem, and 
COPD related symptoms of cough, phlegm, and shortness of breath. Additionally, years 
of smoking and access to health insurance will be interrogated as cofounders.    
Table 2 
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77=Don’t 
know/not sure  
99=Refused 
 
Independent Variable. In this study, sex was the independent variable.  Sex 
attributes were obtained directly from the BRFSS database.  
Dependent variable.  Utilization of breathing tests among the population of 
subjects who have been told that they may have COPD, emphysema or chronic bronchitis 
served as the dependent variable. Breathing tests construct was obtained in a binary 
manner.  Cases who had a response of yes or no to this module were selected for analysis 
Covariates.  The presence of symptoms such as shortness of breath, cough and 
production of phlegm, were considered as covariates due to potential influence on driving 
medical decision towards a breathing tests. Additionally, presence/absence of health care 
coverage can be considered moderating as these can impact access to healthcare 
sequentially testing. These variables can be analyzed as partially mediating or completely 
mediating based on the static nature of either the independent or dependent variable.   
 Study population and missing cases. Study population of subjects with 
knowledge of COPD, emphysema and chronic bronchitis was isolated from the parent 
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2017 BRFSS data set, yielding 37, 577 cases for investigation; described in Table 3.  
Further inclusion criteria of age and response to breathing tests module were applied, 
Figure 2. Considering no significant missing cases were present within the study 
population, no additional mitigation procedure was necessary.  
Table 3  
Subjects with COPD, Emphysema, or Chronic Bronchitis  
 Frequency Percentage  Weighted 
Percentage  
Yes 37,577 8.35 6.51 
 




2,099 0.47 0.46 
 
Refused 197 0.04 0.03 
    
Not Asked, 
missing  
2 - - 
 
Data Analysis Plan 
Analysis Techniques  
All variables used for investigation are nominal, and therefore appropriate 
techniques were employed to describe the population while evaluating by SPSS 25 
statistical software. 
Descriptive statistics. The population of interest was described by assessing 
frequencies, proportions, and percentages within the broad cohort of subjects who have 
been told they have COPD, emphysema or chronic bronchitis.  
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Bivariate analysis. I used bivariate chi-square methodology for RQ1, assessing 
relationships between males and females who have received a breathing tests.  The 
dichotomized phenomena of interest, breathing test, requires Pearson’s chi-square test as 
the primary bivariate analysis (Science Direct, 2019). 
Multivariable analysis. Multivariate analysis allows for focus on multiple 
variables of interest and appropriate methodology for RQ2 & RQ3 in assessing 
relationship between opportunity of breathing tests among males and females with COPD 
related symptoms and presence of health insurance, respectively. For this test, BLR was 
the appropriate methodology (Laerd, 2018). 
Rationale for Covariate Inclusion 
 Inclusion of population demographics such as age, race/ethnicity, income and 
level of education as it relates to opportunity towards a breathing tests is a confounding 
factor as these may influence health literary and therefore understanding of necessity to 
engage with the healthcare system.  As important upstream determinants of health, 
covariates must be considered within the investigation. 
Interpretation of Results 
Interpretation of results was based on odds ratios of receiving a breathing tests 
between males and females. Secondarily, odds ratios of receiving breathing tests in the 
presence/absence of health insurance and applicable symptoms was assessed.  Analyses 
was considered at 95% confidence intervals. All statistical analysis were performed by 
SPSS version 25 available through Walden University.  
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Threats to Validity 
BRFSS is a comprehensive US generalizable dataset, yet has several limitations 
requiring notice.  Primarily, subject selection methodology is random to non-
institutionalized adults 18 years and older selected via outbound calling; subjects wishing 
not to participate may have unique attributes and are excluded from the dataset.  
Additionally, because the variables are collected via self-reported survey, validity of 
recall, non-response, health and literacy, missing information may all impact validity of 
the investigation. 
External Validity 
 Respective to external validity, broader generalizability of investigation was 
considered. With a broad subject footprint across BRFSS collection territories, inferences 
drawn from this investigation may describe breathing tests patterns across the US 
between males and females while also considering influence by COPD related symptoms 
and presence of health insurance.  Potential threats to external validity include penitential 
selection bias in the subject population as BRFSS is a wide surveillance instrument, as 
opposed to a specific COPD focused data set.  
Internal Validity 
Internal validity assesses the capacity of the data set to accurately support the 
research question. In this investigation, due to the survey nature of the data set, subject 
recall bias may have posed a potential threat.  Additionally, subjects may fail to 
accurately understand COPD related questions and either under or over report their 
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disease as well as testing and symptomatology. Internal validity was confirmed as much 
as possible by using BLR. 
Ethical Procedures 
This study underwent an expediated Walden Institutional Review Board review 
due to the deanonymized nature of the data and lack of active intervention arm (approval 
# 08-08-19-0628769).  Data were collected by the CDC according to the ICH and broad 
clinic research standards.  All data were handled in a sensitive and secure manner.  There 
was no active collection of samples, or identifiable HIPPA protected health information.  
All data will be kept in two step authenticated electronic media for 5 years.  However, 
this is an open source dataset and the integrity of the data is maintained and cannot be 
manipulated, creating any additional risk. 
Summary 
Section 2 described methodological details implicating this investigation. By 
statistical testing, signal towards receiving a breathing tests between males and females 
was evaluated. Influence of COPD-related symptoms and presence of health insurance as 
covariates were assessed.  Ethical considerations and mitigations were discussed. In 
Section 3, a description of the population and study results are presented. 
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Section 3: Presentation of the Results and Findings 
Introduction 
COPD is prevalent and burdensome, demanding attention from multiple 
stakeholders, including patients, families, society, healthcare system, and policy makers. 
Even though COPD is non-selective in terms of sex, meaning both males and females can 
develop the illness, morbidity and mortality are experienced differently by women 
(DeMeo, 2018). In the last decade, there is an observed divergence in mortality resulting 
from COPD, with women leading in terms of number of deaths (CDC, 2015). Mainly as a 
byproduct of long-standing societal beliefs and perceptions involving tobacco smoking, 
females are perceived to be less likely to have COPD then their male counterparts. 
Section 3 includes bivariate and chi-square analyses assessing breathing tests trends 
among men and women who have been told by a healthcare provider that they have 
COPD.  Additionally, the influence of common COPD symptoms such shortness of 
breath, phlem, and coughing and presence of health insurance were evaluated through 
multivariable analysis.  Finally, an explorative quasi-simulation of USPTF spirometric 
recommendation of active case finding was conducted via chi-square analysis between 
males and females who admit to having all COPD-related symptoms. Also, in this 
section, a summary of all findings will be included. 
Data Collection of Secondary Data Set 
CDC coordinated via random telephone samples health-related behavior and 
chronic disease data across 50 states and territories by the annual BRFSS. Sampling for 
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these data sets involved both land and cellular outbound random calls to 
noninstitutionalized adults who were older than 18.  The current study used 2017 data.   
Time Frame and Response Rates 
Data collection for the 2017 cohort was operationalized between January 1 and 
December 31, 2017.  The Pew Research Center (2012) determined that telephone survey 
participation rates continue to decline in comparison to live surveys.  CDC has managed 
to produce a dataset with comparable and higher than average participation while 
balancing representation of landline and cellular participants, with rates of 45.3% for 
landline and 44.5% for cellular participants. Furthermore, sample-weighing 
methodologies promote overall population appropriateness and overall generalizability. 
The total combined BRFSS 2017 sample prior to study cohort extraction was 450,016 
cases. 
Discrepancies in the Data Set 
 The original dataset lacked specificity to the research questions respective to 
participation in breathing tests as diagnostic procedure for COPD in cases who have been 
told that they have the illness. A specific cohort to support analysis was extracted; 




Figure 2. Study cohort selection algorithm 
From the initial sample, cases who responded ‘yes’ to knowledge of COPD yielded 37, 
577 cases, or 8.35% of the cohort. Because screening breathing tests is seldomly utilized 
for reasons aforementioned in general practice, and the research question is anchored on 
knowledge of this procedure, those cases with the missing/don’t know/refused response 
to ‘Have you ever been given a breathing tests to diagnose breathing problems?’ were 
extracted, producing 6,501 evaluable cases.  Within this cohort, 61.7% were responses 
from women; male and female cases were weighed 1:1, giving an equal opportunity for 
evaluation between the sexes.  Because COPD develops in adulthood, pediatric and 
adolescent cases were removed, only allowing participation of subjects 35 years and 
older. The final evaluable cohort of n = 6334 was used for analysis. 
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Descriptive Demographics and Univariate Analysis of Sample  
 The study sample demographics are described in Table 4.  The majority of the 
sample was over the age of 55 and therefore appropriate for the disease under 
investigation.  While diverse ethnicities are represented, the majority of the sample is 
Caucasian.  Most of the sample is married, divorced, or widowed.  Distribution of income 
is heterogeneous, and the sample represents a diverse socioeconomic cohort.  A large 
proportion of the sample has completed high school and some college.  
Table 4 
Cohort Demographics  
Variable Males Females 
 N % N % 
Age  (3129) 50.0 (3124) 50.0 
35-44 years 178 5.7 180 5.8 
45-54 years 378 12.1 439 14.0 
55-64 years 926 29.6 847 27.1 
65 and up 1647 52.6 1659 53.1 
Race/Ethnicity     
White 2538 81.1 2516 80.5 
Black 228 7.3 261 8.4 
Other, non-Hispanic       104 3.3 100 3.2 
Multiracial  83 2.6 66 2.1 
Hispanic 103 3.3 113 3.6 
dk/refused  74 2.4 68 2.2 
Marital Status     
Married 1471 47.0 1038 33.2 
Divorced 750 24.0 773 24.7 
Widowed 401 12.8 877 28.1 
Separated 101 3.2 131 4.2 
Never married 317 10.1 223 7.1 
Unmarried 75 2.4 61 2.0 
Refused 13 0.4 23 0.7 
Income     
<$10,000 225 7.2 321 10.3 





<$20,000 404 12.9 377 12.1 
<$25,000 364 11.6 366 11.7 
<$35,000 317 10.1 309 9.9 
<$50,000 384 12.3 310 9.9 
<$75,000 358 11.4 240 7.7 
>$75,000 382 12.2 202 6.5 
Don’t know  211 6.7 402 12.9 
Refused 199 6.3 241 7.7 
Education Level     
Never attended school, 
only kindergarten 
4 0.1 6 0.2 
Grades 1-8, elementary 157 5.0 131 4.2 
Grades 9-11, some high 
school 
318 10.2 346 11.1 
Grade 12 or GED, high 
school graduate 
1051 33.6 1075 34.4 
College 1-3 years, some 
college 
878 28.0 1006 32.2 
College 4 years or more, 
college 
708 22.6 549 17.6 
Refused 13 0.4 12 0.4 
 
General health history and access to healthcare coverage is described in Table 5. 
Few participants described being in excellent health. A larger percentage of the 
population, ≥ 50% report fair and poor general health. The majority of the cohort, ≥ 90%, 
acknowledge some presence of healthcare coverage. The type of insurance is beyond the 
scope of this study. 
Table 5 
Related Health History  
Variable Males Females 
 N % N % 
General Health  (3129) 50.0 (3124) 50.0 
Excellent 121 3.9 97 3.1 
Very Good 389 12.4        400 12.8 





Fair 930 29.7 994 31.8 
Poor  779 24.9 758 24.3 
Don’t Know 11 0.3 9 0.3 
Refused  1 0.0 3 0.1 
Health Care Coverage     
Yes 2904 92.8 2910 93.2 
No 221 7.1 209 6.7 
Don’t Know  3 0.1 2 0.1 
Refused   1 0.1 2 0.1 
 
 Table 6 portrays COPD related history of the sample. Unitarization of smoking 
tobacco is explained by the lifetime tobacco history of utilization between 1-76 years;  
81.3% of males suggest they have smoked within the specified range and only 69.1% of 
women. Conversely, 26.1% of the women indicate never smoking, or less than 1-year 
exposure, far less than males. A mere 15.4% fit within this description.  While this cohort 
is all cases who have COPD, far less exposure to tobacco is observed in women. 
Table 6 
 
COPD Related History 
Variable Males Females 
 N % N % 
Lifetimes Years of 
Smoking Tobacco 
(3129) 50.0 (3124) 50.0 
1-76 years      2545       81.3 2161 69.1 
Never smoked/less than 1 
year 
480 15.4 815 26.1 
Don’t know 99 3.2 139 4.4 
Refused  5 0.2 9 0.3 
Previous Diagnosis of 
Asthma  
    
Yes 967 30.9 1386 44.4 
No 2132 68.1       1719 55.0 
Don’t Know 30 1.0 19 0.6 
Presence of Cough      
Yes 1563 50.0 1733 55.5 





Don’ Know  11 0.3 7 0.3 
Presence of Shortness of 
Breath  
    
Yes 2230 71.3 2428 77.7 
No 883 28.2 678 21.7 
Don’t Know 14 0.5 17 0.5 
Refused  1 0.0 1 0.0 
Presence of Phlem     
Yes       1489 47.6      1484 47.5 
No 1617 51.7 1623 52.0 
Don’t Know 22 0.7 16 0.5 
     
Far less men, 30.9%, reported a previous diagnosis of asthma in comparison to 44.4% of 
women. Shortness of breath appears to be the most commonly described COPD symptom 
among men and women, with over 70% of both sexes reporting.  Cough and phlem are 
experienced by both males and women similarly at over 45% for all. 
Representativeness of the Sample  
BRFSS 2017 captured landline and cellular phone respondents across all 50 States 
as well as US Territories. Within this sample, 8.35% of the cases reported having COPD; 
CDC reports state specific prevalence ranging from 5%-9%. This cohort is representative 
of national trends.  Initial sample overrepresented women, similarly, exhibiting what is 
commonly observed.  Demographics of the cohort specific to age, socioeconomic status, 
marital status, level of education and access to healthcare are all generalizable to 
nationally reported data for this patient population (CDC, 2016). 
Study Results 
 Recognizing the observance of COPD related symptoms as well as presence of 
healthcare coverage within the sample, inclusion of these constructs within the model is 
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justified.  The following subsections include statistical assumptions and results of the 
three research questions as well as explorative analysis.  
RQ1 
 RQ1 tested for a difference in the utilization of breathing tests between men and 
women who have been told by a clinician that they have COPD. 
 Statistical assumptions.  For RQ1, Pearson’s chi-square test was applied. Six 
assumptions for a chi-square test are (a) data reported as frequencies or counts, (b) 
variables are mutually exclusive, (c) each case may only be counted once, (d) study 
groups are independent, (e) variables are dichotomous and categorical & (f) values of cell 
expected should be five or more in at least 80% of the cells (McHugh, 2013). All 
necessary assumptions for this test are met as data are categorical, mutually exclusive, 
cases independently represented, and more than five cell counts are analyzed. 
 Crosstab and effect size results.  Table 7 displays bivariate analysis for RQ1. Of 
the overall cohort, 82.56% of the cases have reported participation in a breathing tests. 
However, there appears to be a difference in utilization of breathing tests between males 
and females, with chi-square p-value approaching significance of p<0.063.  To further 
support findings from the initial chi-square analysis, Fisher’s Exact Test (utilized to 
determine whether a non-random association exists between two categorical variable) 
suggested a significant p<0.034.  Cramer’s V computation produced an effect size= 














n  (%) 
         Χ2 
 




Sex          
Males                  2111      
(83.4) 
 
518     
(16.6)    
    
Females 2552      
(81.7) 
573    
(18.3) 
    
       3.444 <0.063 <0.034 0.023 
(<0.063) 
  
Figure 3 visually displays responses of males and females respective to experience with 
breathing tests. There are less women receiving a breathing tests.  
 
Figure 3. Prevalence of breathing tests between males and females  
Hypothesis test results.  There is a moderately significant association between 
independent variable of sex and dependent variable of participation in breathing tests (χ
2 
= 3.44, p = 0.063), as displayed in Table 7, thus the null hypothesis for RQ1 is rejected. 
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Fisher’s exact test and effect size further support rejection of the null hypothesis 
suggesting that there is an association between the variables.  
 Based on the results of Pearson’s chi-square and Fisher’s exact test, the null 
hypothesis is rejected, denotating, there is a difference in terms of use of breathing tests 
between males and females, with less women participating in the testing.   
RQ2 and RQ3 
RQ2 assessed for a difference in use of breathing tests between men and women 
who have been told by a clinician that they have COPD and related symptoms (cough, 
shortness of breath and phlem). 
RQ3 assessed for a difference in use of breathing tests between men and women 
who have been told by clinicians that they have COPD and have access to healthcare. 
Statistical assumptions.  For RQ2 and RQ3, BLR models were used to assess 
relevance of COPD-related symptoms and healthcare insurance in terms of access to 
breathing tests. These covariates were tested independently and then together to realize 
the most appropriate model. Six assumptions for BLR include (a) binary dependent 
variable, (b) independents observations, (c) little or no multicollinearity in the 
independent variable, (d) linearity of independent variable, and (e) large sample size 
(minimum of 500; Statistic Solutions, 2019).  All of the necessary assumptions for this 
methodology were met, since dependent variable is dichotomous, cases are independent 
with no multicollinearity and n=6,334.  
BLR results for RQ2.  COPD symptoms of cough, shortness of breath and phlem 
all displayed a positive significant predictive influence of receiving a breathing tests as is 
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evident by positive regression weight (B) and odds ratio (OR), p<0.000. Conversely, a 
patient’s sex has a negatively influences receipt of breathing test; females are 15.9% 
more likely not to have the breathing tests compared to males (OR=.841, CI 95%: 0.739-
0.961).  Nagelkerke R2=0.044 suggests that model explains roughly 4.4% of the 
variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a 
p=0.000, suggesting that the model is a poor fit. 
Table 8 
BLR for Breathing Tests with Predictors Sex, Cough, Shortness of Breath, and Phlem 
 B S.E. Wald 
p 
value 
 95% C.I. for 
OR 
OR Lower Upper 
 Sex  -0.173 0.068 6.468 0.011 0.841 0.739 0.961 
Cough 0.222 0.065 15.878 0.000 1.249 1.119 1.393 
Shortness of Breath 0.485 0.053 84.456 0.000 1.205 1.464 1.800 
Phlem 0.187 0.049 14.592 0.000 1.623 1.095 1.327 
 
Answer to RQ2.  Analyzing results of the binomial regression model, null 
hypothesis attached to symptoms of cough, shortness of breath and phelm having no 
influence on receiving a breathing tests is rejected; all symptoms have a positive odds of 
increasing testing, while sex, in the same model, displays a negative influence. 
 BLR results for RQ3. Presence of healthcare coverage significantly increases the 
odds of breathing tests with OR = 1.741, p < 0.000.  As in the original model, sex 
displayed a negative influence of OR = 0.883, but this is a marginally significant result (p 
= 0.064).  Nagelkerke R2=0.012 suggests that model explains roughly 1.2% of the 
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variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a 
p=0.003, suggesting that the model is a poor fit. 
Table 9 
BLR for Breathing Tests with Predictors Sex, and Healthcare Coverage 
 B S.E. Wald 
p 
value 
 95% C.I. for 
OR 
OR Lower Upper 
 Sex  -0.124 0.067 3.430 0.064 0.883 0.775 1.007 
Health Care 
Coverage  
0.554 0.096 33.679 0.000 1.741 1.444 2.099 
 
Answer to RQ3. Null hypothesis of no difference in utilization of breathing tests 
in subjects with healthcare coverage is rejected.  Health care coverage increases the odds 
of testing by 74.1% (OR=1.741, 95% CI: 1.444-.2.099).  
Aggregate multivariate regression model. All covariates of sex, COPD-related 
symptoms, and presence of healthcare coverage were included in the final analysis, with 
results presented in Table 10.  All covariates were significantly associated with breathing 
tests uptake, with health care coverage having the highest influence (OR=1.747, 95% CI: 
1.448-2.107). Nagelkerke R2=0.055 suggests that model explains roughly 5.5% of the 
variability of the outcome. Hosmer Lemeshow of the goodness of fit test produces a 
p=0.000, suggesting that the model is a poor fit. 
Table 10 





 B S.E. Wald p value 
         95% C.I. for OR 
OR Lower Upper 
 Sex  0.175 0.068 6.544 0.011 0.839 0.074 0.959 
 





0.484 0.053 82.957 0.000 1.622 1.462 1.800 
Phlem 0.193 0.049 15.390 0.000 1.212 1.101 1.335 
 
 Health Care 
Coverage 
0.558 0.196 33.976 0.000 1.747 1.448 2.107 
 
Explorative Analysis 
 The USPTF (2017) suggested that clinicians should utilize active case finding in 
patients who have a risk factor for developing COPD and are symptomatic. In this 
explorative analysis, from the above cohort, only cases responding ‘yes’ to COPD 
symptoms of cough, shortness of breath, and phlem were selected. Through this analysis, 
I was able to assess whether the frequency of breathing tests is higher in symptomatic 
patients and if the variability in sex is mitigated. Applying supplementary case inclusion 
criteria, an explorative analysis produced a sample of n=2100. 
Statistical assumptions.  For this analysis, chi-square methodology was 
implemented; assumptions were previously described.  
Crosstab and effect size results. Out of the original cohort of over 6000 cases, 
only 2100 reported symptoms of shortness of breath, cough, and phelm. Of these, 88.71% 
have had a breathing tests. Applying chi-square testing to assess if there a difference in 
the breathing tests participation between symptomatic males and females yields a non-
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significant p < 0.239, further analysis described in Table 11 and Figure 4. Fisher’s exact 
test provides a nonsignificant p < 0.241.  Cramer’s V computation produced an effect size 
of 0.026, suggesting a moderate association between sex and breathing tests. 
Table 11 










n  (%) 
         Χ2 
 




Sex          
Males                  893      
(89.5) 
 
104     
(10.4)    
    
Females 970      
(87.9) 
133    
(12.05) 
    
       1.384 <0.239 <0.241 0.026 
(<0.239) 
 
Figure 4. Prevalence of breathing tests between symptomatic males and females 
Answer to explorative analysis. Of the symptomatic patients, a higher 
percentage was observed to participate in a breathing tests. Furthermore, previously 
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detected differences in terms of tests between males and females was mitigated by the 
presence of symptoms as suggested by the non-significant χ
2 
= 1.384, p = 0.239. 
Summary  
Section 3 included results and findings of this doctorial research.  This segment 
reiterated the study purpose, sample selection schematics, cohort demographics, and 
COPD-related history and descriptions. This research interrogated the BRFSS 2017 
dataset, with participation in breathing tests as the dependent variable and sex, COPD 
symptoms, and healthcare coverage as independent variables and covariates. 
Significant findings involving female sex negatively associating with breathing 
tests were further supported through binomial regression analysis with inclusion of 
COPD-related symptoms and presence of health insurance.  In a combined model of 
select independent variables, odds ratio of breathing tests increased, with health insurance 
and shortness of breath being leading influencers. An explorative analysis of 
symptomatic adults produced a higher use of breathing tests within this subgroup.  
A comprehensive analysis and interpretation of results will be detailed in Section 
4.  Section 4 offers an overview of analyses, study limitations, recommendations, 
applications to theory and literature, and opportunities for social change.  
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Section 4: Application to Professional Practice and Implications for Social Change 
Introduction 
The purpose of this quantitative cross-sectional investigation was to assess 
breathing tests patterns between males and females with known COPD status.  Inclusion 
of COPD specific symptoms as well as access to healthcare insurance were also 
considered in the model as these covariates may be important in terms of 
recommendation for screening.  Moreover, COPD-specific symptoms and healthcare 
coverage increase the odds of participation in breathing tests in both sexes. Section 4 
includes Key Interpretation of Findings, Limitations of the Study, Recommendations for 
Future Research, and Implications for Practice and Social Change. 
Interpretation of Findings  
Analysis of the BRFSS 2017 data set, cases with known COPD and responses to 
breathing tests modules, indicated a significant disproportional use of breathing tests 
between males and females. Sex was a negative influence on the odds of breathing tests 
(OR=0.839, 95% CI: 0.0735-0.959), while symptoms and healthcare coverage were both 
positive significant influencers. This combined model revealed healthcare coverage 
increasing the odds of breathing tests by 74% (OR = 1.747, 95% CI: 1.448-2.107), and 
shortness of breath by 62% (OR = 1.622, 95% CI: 1.462-1.800).  In the following 
subsections, I will associate findings of the literature and the SEM.   
Findings in Literature  
An in-depth review of the literature alludes to a broader problem of COPD 
diagnostic patterns as nearly half of the 24 million Americans with symptoms of 
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obstructive lung disease remain undiagnosed (NHLBI, 2012). Utilization of a breathing 
tests as a means of confirmation is similarly deficient. Results of this study propose that 
sex may have an influence on attaining a breathing tests in a patient with COPD, 
adversely impacting women.  Symptoms and favorable access to healthcare add further 
weight. 
Sex. There is an overall disparity in terms of experience of women with COPD.  
Multiple analyses confirm a greater proportion of women are burdened with symptoms of 
COPD, experience morbidity at a younger age then men, as have higher overall mortality 
due to COPD (DeMeo, 2019).  To date, this is the first quantitative analysis explaining 
differences in terms of use of breathing tests for women.  A secondary analysis of the 
BRFSS 2017 dataset including cases with known COPD and responses to breathing test 
modules yielded an overall overrepresentation of women with the disease. Cohort was 
weighted by sex, allowing for an equal chance of selecting male and female responder.  
Overall use of breathing tests in the study sample was 82.56%, higher than what is 
reported nationally.  Of this group, 83.4% of men received the testing, compared to 
81.7% of women.   
COPD symptoms. The USPTF (2017) suggested active case finding to be 
practiced by clinicians with the intent to identify candidates for COPD screening, 
including process of a breathing tests. Symptoms are objective and generally begin slow, 
progressing over time; therefore, it may be difficult for the patient to recognize and 
further attribute symptoms to COPD (Rennard, 2015).  Price et al (2016) said that 
patients will report being asymptomatic when questioned about COPD, yet, report 
49 
 
limitations of activity due to shortness of breath, smoking status, and/or fitness level.  
While patients’ perception regarding symptoms and clinicians’ insights involving 
potential disease may have diverse variability, the current investigation confirms that 
presence of symptoms increases the odds of breathing tests. This finding is suggests that 
physician-patient decisions towards spirometry are productive, leading to an increase in 
use of these important tests. 
Healthcare coverage.  In 2010, President Barak Obama signed the Patient 
Protection and Affordable Care Act into Law, intending to expand healthcare coverage to 
more than 29 million Americans.  Those who lack health insurance are less likely to 
engage with the healthcare system for preventative and screening measures, as these 
services are expensive within the US health care system. Furthermore, lack of health 
insurance will lead to delays in sick care, leading to potential detrimental and expensive 
outcomes (APHA, 2020).  With a myriad of professional societies advocating for 
increases in the use of spirometry to adequately screen for COPD, the literature specific 
to impact of health insurance on breathing tests is sparse.  In this study, presence/absence 
of health insurance were included as a covariate in the model, yielding OR = 1.741, p < 
0.000 (95% CI: 1.444-2.099), suggesting a patient’s presence of health insurance 
increases the probability of receiving breathing tests.   
Combined model.  Patterns describing receipt of breathing tests to screen for 
COPD are complex and overlapping.  An aggregated model involving relevant covariates 
of symptoms and healthcare coverage was developed.  There is no literature available 
specifically involving breathing tests; however, results of aggregate multivariable 
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analyses clearly indicated that the primary construct of sex and covariates of symptoms 
and healthcare coverage had a significant influence on the breathing tests.   
Symptomatic cohort.  Little evidence is available on the influence of sex on 
spirometry. From an older investigation by Chapman et al. (2001) findings described 
hypothetical female patients with same impairment and risk as males offered less 
opportunity for breathing tests (Chapman, 2001). Because USPTF active case finding is 
heavily weighed on symptoms, it is of interest if sex biases persist among symptomatic 
patients.  In this study, the symptomatic cohort is smaller (n=2100) displayed an overall 
higher utilization of breathing tests. Moreover, the differences observed between the 
sexes are no longer significant. This result is different than what was described by 
Chapman in 2001 in that both symptomatic males and females are equally participating in 
this procedure. It is promising that nearly 19 years of knowledge and advocacy focused 
on identifying COPD within population has brought symptoms to the forefront of aiding 
disease screening. 
Findings to Social Ecological Framework 
 In this study, SEM was implemented to organize attitudes and beliefs towards 
breathing tests in cases with known COPD.  Biases in terms of public policy are beyond 
the scope of this study; however, trends and inferences can be drawn.  On an individual 
level, at the core of the SEM, patients’ beliefs and health literacy may drive their 
understanding and actions towards engaging with the healthcare system.  While the 
results of this study are not causative, it is apparent that women in the COPD cohort are 
participating in breathing tests less than males; this may be influenced by differences in 
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perspectives and action at the individual patient level. For example, women may consider 
their symptoms to result from being out of shape, possibly neglecting their previous 
smoking history, while males are more likely to correlate smoking with symptoms, 
seeking care.   Long-standing perceptions of the medical community considering male-
dominated diseases may similarly influence recommendations to partake in tests. 
Broadening the findings to the interpersonal, organizational, and community levels, both 
individual and societal influences may shape how both patient groups and care providers 
gather COPD information. Even though COPD is prevalent, burdensome, and costly to 
the system, wider screening policy is lacking. Early case finding regarding patients at risk 
with symptoms mitigated sex biases observed in this heterogeneous cohort. This may not 
serve younger patients and women where symptoms can be correlated with other 
impairments.   
 Access to healthcare was explored as a covariate within the study as literature has 
suggested that absence of health insurance can deter engagement with the healthcare 
system and decision to screen.  These barriers can inhibit individual level decisions, 
spanning to systemic levels, selecting to recommend testing to patients based on health 
insurance access. Results from this study suggest presence of health insurance, in simple 
model with just sex as a construct and those more complex inclusive of COPD 
symptoms, increase probability of acquisition of breathing tests. Similarly, existence of 
health insurance may influence multiple levels within the SEM.   
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Summary of Key Findings and Interpretations 
 From the BRFSS 2017 survey, a cohort of cases with knowledge COPD and 
response to breathing tests module produced an overall breathing tests participation rate 
of 82.56%. Bifurcating these into male and female categories, a moderately significant 
divergence was identified, negatively affecting women. Introducing COPD-specific 
symptoms and presence of health insurance into a regression model further reinforced 
influence of symptoms and presence of health insurance the likelihood of breathing tests.  
In an explorative analysis, breathing tests participation between males and females 
among symptomatic cases reveled differences in rates between the sexes were alleviated.   
Limitations of the Study 
An appreciation of study limitations is necessary as results need be interpreted 
with caution when considering generalizability, validity, and reliability. An important 
limitation of this study is the data sample, BRFSS, which is produced from a large 
population-based survey. As a general random sample, cases are not selected to represent 
a particular disease, therefore, query concerning specific screening procedure may 
introduce a challenge with health literacy and recall bias resulting from self-reporting by 
the participants.  Without an exact medical record capturing a diagnosis code and 
breathing tests procedure code, it is difficult to ascertain whether in fact the tests was 
performed, and if, upon diagnosis. As such, results are reliant on the subjects’ ability to 
adequately recall, understand disease in question and sequential testing and symptom 
modules affiliated.   
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Another limitation of the presents study was that the regression models had a poor 
fit, based on the values from the Nagelkerke and Hosmer Lemeshow tests. These findings 
underpin the complexity of the disease, social and medical constructs contributing to the 
testing decision. Therefore, future research must work towards a larger sample size and 
consideration of inclusion of additional variables such as type of insurance (Medicare 
versus private), age and education level of the patient. While these constructs were 
assessed by descriptive analysis, supplying demographics of the cohort, inclusion of these 
variables into the research question, and therefore statistical analysis, may offer a 
potentially closer model on influence towards receiving a breathing tests.   
An ecological fallacy is possible as multilevel information is aggregated and the 
sample is heterogeneous. Furthermore, consideration of the sample size must be noted, 
following application of inclusion criteria, previously described, a small sample of cases 
was utilized, therefore interpretation of statistical testing must be hypothesis generating 
and requiring further investigation in a larger cohort.  Finally, the findings of this study 
should be limited to the US and its territories due to the demographic of the original 
sample, and therefore may not be generalizable to global trends. 
Implications for Professional Practice and Social Change 
There are several lessons from this study demanding further investigation and 
intervention. Recognizing that COPD is burdensome to patients, their families and 
society at large, its necessary to recognize that varied groups may experience this disease 
differently; therefore, our approach to improving outcomes must be heterogeneous 
enough to differentiate and support these nuances. To date, this is one of the first 
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quantitative studies which has specifically focused on the COPD breathing tests 
experience of women in comparison with men, adding context to practice and society 
while laying foundation for future research.  
Professional Practice  
Learning from historical examples in other therapeutic areas, it is clear that 
prevention of disease and education on wellness is far more beneficial than battling an 
established chronic illness.   The next best scenario, early identification, allows for 
education on potential risks, hazards, coaching on lifestyle, habit modification and 
potential therapeutic intervention. Conversely, a delay in diagnosis may lead to disease 
progression, morbidity, disability and potentially death.  In the case of COPD, the 
pressing underdiagnosis is concerning, as is the, is the experience of the disease by 
women. As is signaled by this study, women with COPD are participating in breathing 
tests less than men; in addition, a presence of symptoms increases the potential of 
breathing tests.  The medical community begins to consider diagnosis of COPD in the 
middle ages; however, women are far more symptomatic earlier in life (DeMeo, 2019).   
Taking lessons from this study, recommendations can be implemented by 
practitioners, while additional evidence needs to be generated by the research 
community.  Continuing to focus on early disease identification, training modules via 
continuing medical education (CME) should be updated describing COPD related trends, 
specifically elevating differences in disease presentation, onset of symptoms while 
brining attention to potential delay to breathing tests in women.  These modules can serve 
as productive medium to update provider understanding of COPD, elevating 
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heterogeneity of disease and variability in men and women. Anchoring on the 
constructive influence of symptoms on probability of receiving breathing tests, utilization 
of symptom impairment validated questionnaires such as COPD Assessment Test (CAT) 
can further guide productive discussions between clinicians and patients.  Symptom 
questionnaires can be a helpful tool for both patients and clinicians alike, elevating 
presence and burden of symptoms, thereby paving the way towards a productive and 
targeted conversation during a clinical visit. 
Additional research is necessary to further explore screening disease patterns in 
COPD, with a focus on women.  Identifying a COPD specific database, ideally one with 
health care records and claims available, can offer direct analysis of diagnosis and 
procedure codes, thereby reducing certain limitations and greatly increasing reliability of 
these findings.  Additionally, it would be prudent to also peel away at the causative 
perceptions of COPD by clinicians and patients, offering greater understanding and 
opportunities of interventions. Employing qualitative methodologies of direct interviews 
and focus groups among societal segments of clinicians and patients with and without 
disease should offer basis of attitudes and beliefs towards COPD and screenings. Finally, 
a mixed methods approach of interviews with clinicians coupled by analysis of actual 
practice patterns would be of interest as perceptions and behaviors must be evaluated 
concurrently, identifying inconsistencies. 
Contribution to Social Change  
 Application of knowledge in the direction of social change stands the capability to 
alter trajectories for society on a broader scale. In the United States, a general 
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stigmatization towards COPD exists and is a product of strong rooted beliefs of tobacco 
utilization. Because the most significant risk factor for developing COPD in the 
developed world is an ongoing decision to engage in a health hazardous activity of 
smoking cigarettes, less empathy, sensitivity and ultimately attention may be given to 
addressing symptoms. Moreover, individuals who have symptoms could be reluctant to 
elevate these for the fear of guilt and shame that may precipitate. In the case of women, 
these beliefs are further complicated by previously described entrenched viewpoints on 
smoking by women and disease patterns.  Insights from this study elevate inclinations 
warranting social attention and change.  
 While breathing tests participation rates in this COPD cohort was relatively high, 
over 80%, these results are much higher than what is anticipated in practice. With nearly 
12 million Americans with symptoms of obstructive lung disease yet lacking appropriate 
diagnosis, ongoing and catalyzed advocacy is essential to elevate COPD as an agenda 
item for health advocates and policy makers. Recognizing that experience of COPD is 
different in women than men, a change in the perceptions is necessary across societal 
levels. Starting broadly, society must recognize that COPD, much like any other chronic 
illness, is burdensome, leading to struggle and disability by the patients while adding a 
strain on families and the healthcare system. Disassembling biases through the means of 
education, working towards awareness can reduce the negative stigmatization towards 
COPD as a whole.  Attention heterogeneity of disease and experience of women must 
similarly take focus and pave the way towards acceptance of prevalence in women.  
Considering that both males and females have a higher probability for receiving tests if 
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symptoms are present, a raised focus on awareness of symptoms by the medical 
community may support more case finding and identification of patients. On a policy 
level, professional society and USPTF must re-visit definition of active case finding, with 
potential discussion into the variability of experience by women. Translating these 
messages to the organizational levels, medical communities should be more vigilant in 
recognizing that disease may present slightly differently in women therefore both male 
and female patients at risk with symptoms may be warranted for breathing tests. 
 Social change stands a better opportunity of success when patients are involved 
and leading the charge. Working through biases that individual patients may be 
experiencing, advocacy and education initiatives within patient communities may lift 
some perceptions, perhaps leading to greater initiative by the patients to screen and have 
more direct conversations with their providers. Large patient advocacy groups such as the 
COPD Foundation can engage and message patient communities in that both men and 
women can develop COPD.  Again, because results of this study suggested that when 
patients have symptoms probability of breathing tests is higher, we must educate patients 
to have greater awareness of their symptoms, correlate to potential disease, and 
communicate their experience to the healthcare team.  An amalgamation of enhanced 
awareness and understanding by the healthcare community alongside engaged and health 
literate patients can be changes necessary to alter trajectories in COPD for all of society. 
Conclusion  
This study identified differences in rates of breathing tests usage among male and 
female patients who have knowledge of COPD. When symptoms and healthcare coverage 
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were added into a multivariate regression model, all had a positive influence on the 
prevalence of breathing tests.  A larger and more targeted COPD sample with access to 
medical records would offer a comprehensive database for quantitative analysis; 
specifically, prevalence of breathing tests use among males and females. Furthering 
testing regarding practice patterns between men and women patients with COPD can 
offer insights to policy makers, health advocates, practitioners, and community where 
areas for intervention can offer opportunities to improve identification and ultimately 
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